For patients with advanced NSCLC harboring epidermal growth factor receptor (EGFR) mutations, EGFR-tyrosine kinase inhibitors (EGFR-TKIs) are usually considered the first-line treatment (3–5). Here, EGFR is linked to non-small cell lung carcinoma.